NCT00428220

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Study Contact:

Study Phase:

Recruitment Status:

COMPLETED

NCT ID:

NCT00428220

Principal Investigator:

Study Type:

INTERVENTIONAL

Official Title:

An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment

Summary

This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.

Eligibility

Inclusion Criteria:

* Must have ended treatment from one of the following sunitinib studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.

Exclusion Criteria:

* See inclusion criteria

Disease(s) and\or Condition(s)

Metastatic Breast Cancer

Advanced Breast Cancer

Metastatic Castration Resistant Prostate Cancer

Metastatic Renal Cell Cancer

Non-Small Cell Lung Cancer

Thyroid Cancer

Advanced/Metastatic Non-Small Cell Lung Cancer

Advanced Gastric Cancer

Gastrointestinal Stromal Tumor

Hepatocellular Carcinoma

Pancreatic Islet Cell Carcinoma

Pancreatic Neuroendocrine Tumor

Primary Purpose

TREATMENT

Intervention/Treatment

- Type: DRUG
- Name: sunitinib
- Description: sunitinib
- Arm Group Labels: A

Sponsor

Pfizer